DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 119 filers reported holding DENALI THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.75 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,652 | -30.1% | 467,851 | +0.0% | 0.02% | -20.0% |
| Q2 2023 | $13,805 | +46.8% | 467,800 | +14.6% | 0.02% | +66.7% |
| Q1 2023 | $9,403 | +35.5% | 408,100 | +63.5% | 0.01% | +33.3% |
| Q4 2022 | $6,941 | -99.9% | 249,600 | -36.4% | 0.01% | -47.1% |
| Q3 2022 | $12,037,000 | +61.3% | 392,200 | +54.7% | 0.02% | +88.9% |
| Q2 2022 | $7,461,000 | +89.2% | 253,500 | +106.8% | 0.01% | +80.0% |
| Q1 2022 | $3,944,000 | +62.8% | 122,600 | +125.8% | 0.01% | +66.7% |
| Q4 2021 | $2,422,000 | -49.8% | 54,300 | -43.2% | 0.00% | -50.0% |
| Q3 2021 | $4,823,000 | +434.7% | 95,600 | +731.3% | 0.01% | +500.0% |
| Q2 2021 | $902,000 | -94.1% | 11,500 | -95.7% | 0.00% | -94.7% |
| Q1 2021 | $15,183,000 | +722.9% | 265,900 | +416.3% | 0.02% | +850.0% |
| Q3 2020 | $1,845,000 | +41.1% | 51,500 | -18.3% | 0.00% | +100.0% |
| Q2 2019 | $1,308,000 | – | 63,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |